Monnier Yan, Farmer Pierre, Bieler Gregory, Imaizumi Natsuko, Sengstag Thierry, Alghisi Gian Carlo, Stehle Jean-Christophe, Ciarloni Laura, Andrejevic-Blant Snezana, Moeckli Raphael, Mirimanoff René-Olivier, Goodman Simon L, Delorenzi Mauro, Rüegg Curzio
Division of Experimental Oncology, Centre Pluridisciplinaire d'Oncologie, Faculty of Biology and Medicine, University of Lausanne, Switzerland.
Cancer Res. 2008 Sep 15;68(18):7323-31. doi: 10.1158/0008-5472.CAN-08-0841.
Radiotherapy is widely used to treat human cancer. Patients locally recurring after radiotherapy, however, have increased risk of metastatic progression and poor prognosis. The clinical management of postradiation recurrences remains an unresolved issue. Tumors growing in preirradiated tissues have an increased fraction of hypoxic cells and are more metastatic, a condition known as tumor bed effect. The transcription factor hypoxia inducible factor (HIF)-1 promotes invasion and metastasis of hypoxic tumors, but its role in the tumor bed effect has not been reported. Here, we show that tumor cells derived from SCCVII and HCT116 tumors growing in a preirradiated bed, or selected in vitro through repeated cycles of severe hypoxia, retain invasive and metastatic capacities when returned to normoxia. HIF activity, although facilitating metastatic spreading of tumors growing in a preirradiated bed, is not essential. Through gene expression profiling and gain- and loss-of-function experiments, we identified the matricellular protein CYR61 and alphaVbeta5 integrin as proteins cooperating to mediate these effects. The anti-alphaV integrin monoclonal antibody 17E6 and the small molecular alphaVbeta3/alphaVbeta5 integrin inhibitor EMD121974 suppressed invasion and metastasis induced by CYR61 and attenuated metastasis of tumors growing within a preirradiated field. These results represent a conceptual advance to the understanding of the tumor bed effect and identify CYR61 and alphaVbeta5 integrin as proteins that cooperate to mediate metastasis. They also identify alphaV integrin inhibition as a potential therapeutic approach for preventing metastasis in patients at risk for postradiation recurrences.
放射疗法被广泛用于治疗人类癌症。然而,放疗后局部复发的患者发生转移进展的风险增加且预后较差。放疗后复发的临床管理仍是一个未解决的问题。在放疗前组织中生长的肿瘤缺氧细胞比例增加且更具转移性,这种情况被称为肿瘤床效应。转录因子缺氧诱导因子(HIF)-1促进缺氧肿瘤的侵袭和转移,但其在肿瘤床效应中的作用尚未见报道。在此,我们表明,源自SCCVII和HCT116肿瘤且在放疗前的肿瘤床中生长,或通过反复严重缺氧循环在体外筛选得到的肿瘤细胞,恢复到常氧状态时仍保留侵袭和转移能力。HIF活性虽然有助于在放疗前肿瘤床中生长的肿瘤发生转移扩散,但并非必不可少。通过基因表达谱分析以及功能获得和功能缺失实验,我们确定了基质细胞蛋白CYR61和αVβ5整合素是协同介导这些效应的蛋白质。抗αV整合素单克隆抗体17E6和小分子αVβ3/αVβ5整合素抑制剂EMD121974抑制了CYR61诱导的侵袭和转移,并减弱了在放疗前区域内生长的肿瘤的转移。这些结果代表了在理解肿瘤床效应方面的概念性进展,并确定CYR61和αVβ5整合素是协同介导转移的蛋白质。它们还确定了抑制αV整合素是预防放疗后复发风险患者发生转移的一种潜在治疗方法。